Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Tachycardia, Ventricular
- Sponsor
- Ain Shams University
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Number of Participants With Recurrence of Ventricular Tachycardia
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
This study aims at comparing the recurrence rates of ventricular tachycardia ablated after being mapped by 2 different techniques.
Detailed Description
The study participants are patients presented with recurrent ventricular tachycardia. They will be divided into 2 groups in terms of mapping. The first group will use mapping during sinus rhythm to identify late potentials that may be incriminated in the tachycardia circuit. The other group will undergo mapping during right ventricular extrastimulus pacing to unmask hidden potentials. The identified potentials will be ablated in both groups.
Investigators
Mohammad Gamal
Principal investigator
Ain Shams University
Eligibility Criteria
Inclusion Criteria
- •• Patients with structural heart disease; previous myocardial infarction, left ventricular dilatation/systolic dysfunction, or normal left ventricular diameters/ systolic function with evidence of ventricular scar on contrast enhanced-cardiac magnetic resonance or electroanatomic map.
- •Sustained monomorphic ventricular tachycardia documented by 12-lead ECG or implantable cardioverter defibrillator (electrograms resistant to antiarrhythmic drug treatment or requiring implantable cardioverter defibrillator therapies.
Exclusion Criteria
- •• Patients with ventricular arrhythmias attributed to reversible causes.
Outcomes
Primary Outcomes
Number of Participants With Recurrence of Ventricular Tachycardia
Time Frame: 12 months
Recurrence of ventricular tachycardia implies receiving at least one appropriate implantable cardioverter defibrillator therapy or hospital admission due to symptomatic ventricular tachycardia.
Secondary Outcomes
- Number of Participants Who Die From Any Cause (All-cause Mortality)(12 months)
- Number of Participants Who Experience Cardiac Death(12 months)